Mediastinal Mass and Pleural Effusion: different clinical presentations of lymphoma in pediatric age

Autores/as

  • Federica Maria Previtera Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina
  • Simone Foti Randazzese Pediatric Unit, Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina
  • Fabio Toscano Pediatric Unit, Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina
  • Santo Ielo Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina
  • Maria Emanuela Chessari Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina
  • Mariapia Composto Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina
  • Flavia Caime Pediatric Unit, Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina
  • Sara Manti Pediatric Unit, Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina
  • Carmelo Romeo Pediatric Surgery Unit, Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina
  • Malgorzata Gabriela Wasniewska Pediatric Unit, Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina
  • Giuseppina Zirilli Pediatric Unit, Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina

DOI:

https://doi.org/10.13129/1828-6550/APMB.113.1.2025.CCS1

Palabras clave:

lymphoma, leukemia, mediastinal mass, pleural effusion, precision medicine

Resumen

Background: Mediastinal masses and pleural effusions may have different etiologies, from infectious to malignant and autoimmune diseases, originating from the mediastinum or nearby structures. Several signs and symptoms, such as persistent anemia, dyspnea, chronic itching, and mantle oedema, may raise suspicion of a malignant disease. Specifically, lymphomas may be a common cause of both mediastinal masses and pleural effusions.

Case presentation: We report the cases of two children, aged 9 and 13, who were admitted to the Pediatric Unit of AOU “Gaetano Martino” in Messina with pleural effusion and superior vena cava syndrome, respectively. Both had a previous history of SARS-CoV-2 infection a few months prior. Clinical, laboratory and radiological findings suggested the presence of a mediastinal mass, compatible with lymphoma.

Conclusions: Tumors are a rare clinical entity in pediatric age. These cases highlight the importance of an accurate diagnostic workup and the critical role of identifying red flags. Nowadays, precision medicine plays a fundamental role as it uses the knowledge of genetic and biochemical profiles of a disease to tailor diagnosis and therapy for pediatric patients with tumors.

Referencias

1. Mastronuzzi, A., Basso, A., Del Baldo, G., Carai, A., De Salvo, A., Bonanni, A., et al. (2022). Full Sails against Cancer. Int J Environ Res Public Health, 19 (24): 16609. doi: 10.3390/ijerph192416609.

2.Chen, C.H., Wu, K.H., Chao, Y.H., Weng, D.F., Chang, J.S., Lin, C.H. (2019). Clinical manifestation of pediatric mediastinal tumors, a single center experience. Medicine (Baltimore), 98 (32): e16732. doi: 10.1097/MD.0000000000016732.

3.Verma, S., Kalra, K., Rastogi, S., Sidhu, H.S. (2020). Clinical approach to childhood mediastinal tumors and management. Mediastinum, 4: 21. doi: 10.21037/med-19-82.

4. García-Domínguez, D.J., Hontecillas-Prieto, L., Palazón-Carrión, N., Jiménez-Cortegana, C., Sánchez-Margalet, V., de la Cruz-Merino, L. (2022). Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics. Cancers (Basel), 14 (6): 1469. doi: 10.3390/cancers14061469.

5. Honda, M., Yuki, A., Takahiro, H., Chigusa, O., Yuichi, M., Makiko, M., et al. (2023). Predictive risk score of respiratory complications in children with mediastinal tumors: A case-control study. Cancer Med, 12 (2): 1167-1176. doi: 10.1002/cam4.4972.

6. Vo, K.T., Parsons, D.W., Seibel, N.L. (2020). Precision Medicine in Pediatric Oncology. Surg Oncol Clin N Am, 29 (1): 63-72. doi: 10.1016/j.soc.2019.08.005.

7. Psallidas, I., Kalomenidis, I., Porcel, J.M., Robinson, B.W., Stathopoulos, G.T. (2016). Malignant pleural effusion: from bench to bedside. Eur Respir Rev, 25 (140): 189-98. doi: 10.1183/16000617.0019-2016.

8. Lending, G., El Ghani, Y.A., Kaykov, E., Svirsky, B., Cohen, H.I., Altman, E. (2021). Hemorrhagic Malignant Pleural Effusion: Diagnosis, Survival Rate, and Response to Talc Pleurodesis. Indian J Surg Oncol, 12(1): 54-60. doi: 10.1007/s13193-020-01099-2.

9. Porcel, J.M. (2013). Identifying transudates misclassified by Light’s criteria. Curr Opin Pulm Med, 19 (4): 362-7. doi: 10.1097/MCP.0b013e32836022dc.

10. Nossair, F., Schoettler, P., Starr, J., Chan, A.K.C., Kirov, I., Paes, B., et al. (2018). Pediatric superior vena cava syndrome: An evidence-based systematic review of the literature. Pediatr Blood Cancer, 65 (9): e27225. doi: 10.1002/pbc.27225.

11. Tanaka, T., Amano, H., Tanaka, Y., Takahashi, Y., Tajiri, T., Tainaka, T., et al. (2020). Safe diagnostic management of malignant mediastinal tumors in the presence of respiratory distress: a 10-year experience. BMC Pediatr, 20 (1): 292. doi: 10.1186/s12887-020-02183-w.

12. Tannock, I.F. (2023). Precision medicine for children with cancer. Lancet Oncol, 24 (9): 952-954. doi: 10.1016/S1470-2045(23)00386-8.

13. Schwartzberg, L., Kim, E.S., Liu, D., Schrag, D. (2017). Precision Oncology: Who, How, What, When, and When Not? Am Soc Clin Oncol Educ Book, 37: 160-169. doi: 10.1200/EDBK_174176.

Descargas

Publicado

2025-03-19

Número

Vol. 113 Núm. 1 (2025)

Sección

CLINICAL CASE SEMINAR

Licencia

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:
  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).